side effects of semaglutide vs tirzepatide Semaglutide: What's the Difference? — Ryn Journal Tirzepatide vs. Semaglutide for Weight

GLP-1 class safety monitoring should include awareness of these important risks: Pancreatitis : Patients should promptly report severe abdominal pain, with or without vomiting Gallbladder disease : Report symptoms of biliary colic or cholecystitis Acute kidney injury : Maintain adequate hydration, especially if experiencing nausea/vomiting Hypoglycemia : Increased risk when used with insulin or sulfonylureas Suicidal ideation : For patients using Wegovy or Zepbound, monitor for mood changes Patients should be counseled to report any neck swelling, difficulty swallowing, persistent hoarseness, or palpable thyroid nodules, as these warrant evaluation regardless of GLP-1 use

Fluctuations in blood sugar, whether too high or too low, may result in symptoms like lightheadedness

Operative risk in Eisenmenger syndrome is lower than in pulmonary arterial hypertension as patients with Eisenmenger syndrome are able to increase their cardiac output by increasing right to left shunting at the expense of their oxygenation

Understanding Your Eligibility for GLP-1 Medication Before any approval happens, you need to know whether you meet the baseline clinical criteria

Exendin-4 became the chemical scaffold for exenatide, and on April 28, 2005, the FDA approved exenatide (Byetta) for type 2 diabetes the first GLP-1 receptor agonist ever marketed